Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration (Q33495553)

27 July 2017

title

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration (English)

1 reference

27 July 2017

Gerrits CJ

1

1 reference

27 July 2017

Creemers GJ

2

1 reference

27 July 2017

Schellens JH

3

1 reference

27 July 2017

Wissel P

4

1 reference

27 July 2017

Planting AS

5

1 reference

27 July 2017

Kunka R

6

1 reference

27 July 2017

Selinger K

7

1 reference

27 July 2017

de Boer-Dennert M

8

1 reference

27 July 2017

Marijnen Y

9

1 reference

27 July 2017

Harteveld M

10

1 reference

27 July 2017

Verweij J

11

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 March 1996

1 reference

27 July 2017

number of pages

7

1 reference

British Journal of Cancer

inferred from page(s)

published in

1 reference

27 July 2017

volume

73

1 reference

27 July 2017

issue

6

1 reference

27 July 2017

page(s)

744-750

1 reference

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhi

27 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

The current status of camptothecin analogues as antitumor agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Topoisomerase I inhibitors: topotecan and irenotecan

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Camptothecins: from bench research to hospital wards.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Topoisomerase-targeting antitumor drugs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074382

Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II

21 June 2018

1 reference

12 December 2020

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

12 December 2020

High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma

1 reference

12 December 2020

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

12 December 2020

Effects of camptothecin on the breakage and repair of DNA during the cell cycle

1 reference

12 December 2020

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1996.130

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference